Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival

2022 ◽  
Author(s):  
Davide Ciardiello ◽  
Vincenzo Famiglietti ◽  
Stefania Napolitano ◽  
Lucia Esposito ◽  
Filippo Pietrantonio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Wild Type ◽  
Lymphocyte Ratio ◽  
Colorectal Cancer Patients

Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively?

2012 ◽  
Vol 27 (10) ◽  
pp. 1347-1357 ◽  
Author(s):  
Sum-Fu Chiang ◽  
Hsin-Yuan Hung ◽  
Reiping Tang ◽  
Chung Rong Changchien ◽  
Jinn-Shiun Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Curative Surgery ◽  
Lymphocyte Ratio ◽  
Colorectal Cancer Patients

scholarly journals A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

2019 ◽  
Vol 121 (5) ◽  
pp. 378-383 ◽  
Author(s):  
Elena Elez ◽  
Carles Pericay ◽  
Manuel Valladares-Ayerbes ◽  
Inmaculada Bando ◽  
Maria Jose Safont ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Salvage Therapy ◽  
Phase 2 ◽  
Wild Type ◽  
Exon 2 ◽  
Phase 2 Study ◽  
Colorectal Cancer Patients ◽  
Kras Exon

scholarly journals Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens

2013 ◽  
Vol 14 (12) ◽  
pp. 1098-1103 ◽  
Author(s):  
Filippo Pietrantonio ◽  
Federica Perrone ◽  
Pamela Biondani ◽  
Claudia Maggi ◽  
Andrea Lampis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Single Agent ◽  
Wild Type ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document